ArticleFrontiers in oncology2026
Case report and literature review: Golidocitinib as a potential treatment for monomorphic epitheliotropic intestinal T-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare type of non-Hodgkin lymphoma and a highly aggressive malignancy with a median overall survival of 7 months. Meanwhile, owing to the complex and confusing symptoms including nonspecific gastrointestinal symptoms, systemic manifestations and additional clinical manifestations associated with the extraintestinal involvement organs, MEITL is often diagnosed at an advanced stage. We report three cases of MEITL, and searched PubMed indexed articles between 2016 and 2024 for these terms: "MEITL" and "case report". We found that younger patients, those with intestinal perforation, and those who did not receive chemotherapy had worse prognoses. Importantly, we found that treatment with the JAK-1 inhibitor Golidocitinib in combination with the GDP regimen (Gemcitabine, Dexamethasone and Cisplatin) can improve patient prognosis. The study suggests that Golidocitinib could potentially improve the prognosis of MEITL patients by targeting the JAK-STAT pathway, although further validation of its long-term effectiveness is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.